Not Yet Recruiting
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
NCT07388550
- Conditions
- COVID-19, Chronic Disease, Coronaviridae Infections, +15 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States